Merck KGaA signs $1.4B biobuck deal with Caris to expand ADC pipeline

Merck KGaA has become the latest biopharma to swell its oncology pipeline with further antibody-drug conjugate (ADC) potential this week.

The German company has signed up Texas’ Caris Life Sciences for a multiyear collaboration that will see targets identified by Caris and then passed to Merck for preclinical development and beyond. The April 4 release was light on details of the exact nature of these potential targets.